Cargando…

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?

BACKGROUND AND AIMS: Lipoprotein(a) [Lp(a)] and interleuking-6 (IL-6), an inflammation biomarker, have been established as distinct targets of the residual atherosclerotic cardiovascular disease (ASCVD) risk. We aimed to investigate the association between them, and the potential clinical implicatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makris, Anastasios, Barkas, Fotios, Sfikakis, Petros P., Liberopoulos, Evangelos, Filippatos, Theodosios D., Ray, Kausik K., Agouridis, Aris P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500445/ https://www.ncbi.nlm.nih.gov/pubmed/37720252 http://dx.doi.org/10.1016/j.athplu.2023.09.001

Ejemplares similares

The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials
por: Makris, Anastasios, et al.
Publicado: (2022)

High-density lipoprotein cholesterol and multiple myeloma: A systematic review and meta-analysis
por: Makris, Anastasios, et al.
Publicado: (2023)

Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention
por: Koutsogianni, Amalia Despoina, et al.
Publicado: (2022)

Bradycardia and coronavirus disease 2019: What is behind?
por: Barkas, Fotios, et al.
Publicado: (2021)

Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials
por: Barkas, Fotios, et al.
Publicado: (2021)

Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
por: Fuior, Elena Valeria, et al.
Publicado: (2023)

Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis
por: Barkas, Fotios, et al.
Publicado: (2020)

Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
por: Barkas, Fotios, et al.
Publicado: (2021)

Lifestyle Trajectories Are Associated with Incidence of Cardiovascular Disease: Highlights from the ATTICA Epidemiological Cohort Study (2002–2022)
por: Damigou, Evangelia, et al.
Publicado: (2023)

High fish intake rich in n-3 polyunsaturated fatty acids reduces cardiovascular disease incidence in healthy adults: The ATTICA cohort study (2002-2022)
por: Critselis, Elena, et al.
Publicado: (2023)

Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review
por: Barkas, Fotios, et al.
Publicado: (2021)

Statin-associated side effects in patients attending a lipid clinic: evidence from a 6-year study
por: Barkas, Fotios, et al.
Publicado: (2021)

Plant Sterols and Plant Stanols in Cholesterol Management and Cardiovascular Prevention
por: Barkas, Fotios, et al.
Publicado: (2023)

Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study
por: Filippatos, Theodosios D., et al.
Publicado: (2013)

Diet Quality and Consumption of Healthy and Unhealthy Foods Measured via the Global Diet Quality Score in Relation to Cardiometabolic Outcomes in Apparently Healthy Adults from the Mediterranean Region: The ATTICA Epidemiological Cohort Study (2002–2022)
por: Damigou, Evangelia, et al.
Publicado: (2023)

Attainment of multifactorial treatment targets among the elderly in a lipid clinic
por: Barkas, Fotios, et al.
Publicado: (2015)

Anakinra in COVID-19: A step closer to the cure
por: Barkas, Fotios, et al.
Publicado: (2022)

High-density lipoprotein cholesterol: A marker of COVID-19 infection severity?
por: Agouridis, Aris P., et al.
Publicado: (2021)

Dysfunctional high-density lipoprotein: not only quantity but first of all quality?
por: Agouridis, Aris P., et al.
Publicado: (2015)

Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study
por: Anastasiou, Georgia, et al.
Publicado: (2023)

Statin escape phenomenon: Fact or fiction?
por: Barkas, Fotios, et al.
Publicado: (2017)

Effects of increased body weight and short-term weight loss on serum PCSK9 levels – a prospective pilot study
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications
por: Koutsogianni, Amalia Despoina, et al.
Publicado: (2023)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

Electrolyte and acid-base disorders in inflammatory bowel disease
por: Barkas, Fotis, et al.
Publicado: (2013)

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
por: Shapiro, Michael D., et al.
Publicado: (2017)

Metabolic syndrome in antiphospholipid syndrome versus rheumatoid arthritis and diabetes mellitus: Association with arterial thrombosis, cardiovascular risk biomarkers, physical activity, and coronary atherosclerotic plaques
por: Bolla, Eleana, et al.
Publicado: (2023)

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement( )
por: Kronenberg, Florian, et al.
Publicado: (2022)

Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
por: Doi, Takahito, et al.
Publicado: (2023)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Infections Caused by Moellerella wisconsensis: A Case Report and a Systematic Review of the Literature
por: Germanou, Daphnie, et al.
Publicado: (2022)

Association of Lipoprotein(a) With Atherosclerotic Plaque Progression
por: Kaiser, Yannick, et al.
Publicado: (2022)

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
por: Filippatos, Theodosios D., et al.
Publicado: (2017)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease
por: Gao, Shen, et al.
Publicado: (2017)

Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
por: Tada, Hayato, et al.
Publicado: (2019)

Is Lipoprotein(a) the Most Important Predictor of Residual Atherosclerotic Cardiovascular Disease Risk?
por: Wong, Nathan D.
Publicado: (2022)

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
por: Nissen, Steven E, et al.
Publicado: (2022)

Personalized prophylactic anticoagulation in hospitalized patients with Covid-19 – The role of anti-Xa monitoring
por: Kofteridis, Diamantis P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l2f5db6frghcg2rmak3cntsb7r